GlycoMimetics Inc. (GLYC)’s Financial Results Comparing With Evogene Ltd. (NASDAQ:EVGN)

Both GlycoMimetics Inc. (NASDAQ:GLYC) and Evogene Ltd. (NASDAQ:EVGN) compete on a level playing field in the Biotechnology industry. We will evaluate their performance with regards to analyst recommendations, profitability, risk, institutional ownership, dividends, earnings and valuation.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
GlycoMimetics Inc. N/A 0.00 48.27M -1.13 0.00
Evogene Ltd. 1.75M 34.56 20.76M -0.82 0.00

Demonstrates GlycoMimetics Inc. and Evogene Ltd. earnings per share, top-line revenue and valuation.


Table 2 demonstrates the return on assets, net margins and return on equity of GlycoMimetics Inc. and Evogene Ltd.

Net Margins Return on Equity Return on Assets
GlycoMimetics Inc. 0.00% -21.7% -20.9%
Evogene Ltd. -1,186.29% 0% 0%

Analyst Ratings

GlycoMimetics Inc. and Evogene Ltd. Recommendations and Ratings are available in the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
GlycoMimetics Inc. 0 0 1 3.00
Evogene Ltd. 0 0 0 0.00

GlycoMimetics Inc.’s average price target is $23, while its potential upside is 91.03%.

Institutional and Insider Ownership

Insiders owned 0.2% of GlycoMimetics Inc. shares.


In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
GlycoMimetics Inc. -2.13% 6.43% -1.65% -20.74% -49.3% 25.87%
Evogene Ltd. 1.32% 0% -13.13% -21.45% -28.84% 14.65%

For the past year GlycoMimetics Inc.’s stock price has bigger growth than Evogene Ltd.


On 6 of the 10 factors Evogene Ltd. beats GlycoMimetics Inc.

GlycoMimetics, Inc., a clinical stage biotechnology company, focuses on the discovery and development of glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. The company is developing its lead product candidates include rivipansel, a pan-selectin antagonist, which is in Phase III clinical trials for the treatment of vaso-occlusive crisis, a debilitating and painful condition that occurs periodically throughout the life of a person with sickle cell disease; and GMI-1271, an E-selectin antagonist to treat acute myeloid leukemia and other hematologic cancers. It is also developing GMI-1359, a drug candidate targeting E-selectin and CXCR4; and galectin-3 and galectin-9 inhibitors. The company has a collaborative research and development agreement with Pfizer Inc. GlycoMimetics, Inc. was founded in 2003 and is headquartered in Rockville, Maryland.

Evogene Ltd., a biotechnology company, focuses on the enhancement of crop productivity and performance in the United States and Germany. It operates through two segments, Evogene and Evofuel. The Evogene segment develops seed traits, ag-chemical products, and ag-biological products to enhance plant performance. This segment develops seed traits enhancing plant yield and tolerance to abiotic stresses, such as enhanced tolerance to drought, heat, and salinity, as well as seed traits for enhancing plant resistance to biotic stresses, including resistance to diseases, pests, and insects; novel herbicides; and bio-stimulants, which include microbial-based products that are applied externally to the plant for yield enhancement. Its products focus on various crops, such as corn, soybean, wheat, rice, and cotton. The Evofuel segment develops enhanced species of the castor bean plant to serve as a source of feedstock for biofuel and other industrial uses. The company has strategic collaborations with various agricultural companies, including BASF, Bayer, DuPont, Monsanto, and Syngenta that cover 24 products in various stages of development. Evogene Ltd. was founded in 1999 and is headquartered in Rehovot, Israel.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.